Systematic review: caspase‐cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Background Biomarkers hold great promise for detecting chronic liver disease without the use of liver biopsy. Aim To review the usefulness of cytokeratin (CK) 18 fragments, a marker of hepatocyte apoptosis, to predict the presence of chronic liver injury. Methods Available literature identified from PubMed was reviewed. Results Levels of CK18 fragments have been shown to be elevated in hepatocellular carcinoma, viral hepatitis, alcoholic hepatitis, nonalcoholic fatty liver disease and cholestatic liver disease. In the setting of nonalcoholic fatty liver disease, CK18 fragments may distinguish nonalcoholic steatohepatitis from simple fatty liver. Conclusions Undoubtedly, the most promising application of CK18 fragments is currently in nonalcoholic fatty liver disease, and especially for distinguishing patients with nonalcoholic steatohepatitis vs. those with simple steatosis. Further investigations and technical improvements are required to cross the boundary from research to the clinical application of CK18 fragments as a marker of chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Cited by
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312
Karsdal, M. A., Nielsen, M. J., Sand, J. M., Henriksen, K., Genovese, F., Bay-Jensen, A.-C., Smith, V., Adamkewicz, J. I., Christiansen, C., & Leeming, D. J. (2013) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2012.474 · Cited by 279
Gan, L., Chitturi, S., & Farrell, G. C. (2011) · Current Gerontology and Geriatrics Research · doi:10.1155/2011/831536 · Cited by 135
“What Drives Progression to Steatohepatitis (NASH) Once Steatosis Occurs? Significant hepatocyte apoptosis is a feature of NASH and forms the basis of a serum test for caspase3generated cytokeratin-18 fragments (a biomarker of apoptosis), which is being increasingly used to differentiate between patients with NASH and…”
Dasarathy, S., Yang, Y., McCullough, A. J., Marczewski, S., Bennett, C., & Kalhan, S. C. (2011) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328345c8c7 · Cited by 124
Maccioni, L., Horsmans, Y., Leclercq, I., Schnabl, B., & Stärkel, P. (2023) · Alcohol: Clinical and Experimental Research · doi:10.1111/acer.15081 · Cited by 10
Metadata
- Authors
- YILMAZ, Y.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-11-02
- Volume
- 30
- Issue
- 11-12
- Pages
- 1103-1109
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2000737163
- Cited by
- 94
- References
- 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review: caspase‐cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease. https://app.cochat.ai/papers/10.1111/j.1365-2036.2009.04148.x
- The paper
- YILMAZ, Y. (2009). Systematic review: caspase‐cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2009.04148.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.